Search Medical Condition
Please enter condition
Please choose location

Se1 9rt, United Kingdom Clinical Trials

A listing of Se1 9rt, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (535) clinical trials

32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer

This will be an open label, Phase IIa safety study recruiting about 15 patients from at least two sites. All patients will have 32P BioSilicon implanted into the pancreatic tumour as a single implant, using endoscopic ultrasound. The study will examine the safety of an injected activity equivalent to an ...

Phase

0.0 miles

Learn More »

Genetics of Women With Lobular Carcinoma in Situ of the Breast

OBJECTIVES: Primary - Identify inherited variation that predisposes women to develop lobular carcinoma in situ (LCIS) of the breast. - Identify the frequency of these variants and determine the effect they have on tumor risk. - Determine how worthwhile it would be to test for these variants in the clinical ...

Phase N/A

0.0 miles

Learn More »

High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy

OBJECTIVES: Primary - To determine the effect on freedom from disease progression in patients with relapsed multiple myeloma treated with re-induction therapy comprising bortezomib, doxorubicin hydrochloride, and dexamethasone (PAD) followed by a second autologous stem cell transplantation (ASCT) with high-dose melphalan vs low-dose cyclophosphamide consolidation therapy. Secondary - To assess ...

Phase

0.0 miles

Learn More »

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

In this phase I, open-label, multi-arm, multicentre, multi-dose dose escalation study in patients with transdermally accessible tumours; the safety, PK and efficacy of different dosing regimens of LTX-315 will be assessed. Patients will be allocated into 4 separate (parallel) arms depending on the tumour type and the number of lesions ...

Phase

0.0 miles

Learn More »

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.

Phase

0.0 miles

Learn More »

A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.

This is a multi-centre, Phase I clinical trial of the combination of AZD2014 and weekly paclitaxel. Two intermittent BD dosing schedules of AZD2014 in combination with paclitaxel will be evaluated. The 3 days on 4 days off schedule will examine 3 continuous days of AZD2014 per week in combination with ...

Phase

0.0 miles

Learn More »

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

This Phase I, open-label, dose-finding, multicenter study is designed to determine the recommended Phase II dose (RP2D) for the combination of an orally administered Phosphatidylinositol-4,5-bisphosphate 3-kinase beta (PI3K-beta) inhibitor (GSK2636771) with enzalutamide. Subjects with phosphatase and tensin homolog (PTEN)-deficient metastatic castration-resistant prostate cancer (mCRPC) who are receiving a stable dose ...

Phase

0.0 miles

Learn More »

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours

This study will investigate the use of a new drug targeting the DNA repair pathway AZD6738, an ATR inhibitor). Many tumours have lost important DNA repair functions and rely more heavily on a few remaining repair pathways to survive. Preclinical studies indicate that, in these tumours, preventing the function of ...

Phase

0.0 miles

Learn More »

Open-Label Non Randomized Phase 2 Study With Safety Run-In

Open-label, non-randomized, multicentre phase 2 study with a safety run-in evaluating efficacy and safety of PQR309 in patients with relapsed or refractory lymphoma. The maximum tolerated dose (MTD) of PQR309 in patients with advanced solid tumours was defined as 80 mg once daily given continuously (q.d. schedule) in a previous ...

Phase

0.0 miles

Learn More »

A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours

This clinical trial will assess whether a medicine called artemether, currently used at a lower dose to treat malaria, could also be useful in treating cancer. For this trial, the medicine is given in a new way, as a spray under the tongue. This delivery has several advantages, including better ...

Phase

0.0 miles

Learn More »